• head_banner_01

Renewable Design for 3-Nitrophthalic Acid - Semaglutide for Type 2 Diabetes – Gentolex

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We now have our individual sales group, layout team, technical team, QC crew and package group. Now we have strict high-quality control procedures for each procedure. Also, all of our workers are experienced in printing discipline for Acetate De Sodium, Natrium Stearate, Trimethylstearylammonium Chloride 112-03-8, Competitive price with high quality and satisfying service make us earned more customers.we wish to work with you and seek common development.
Renewable Design for 3-Nitrophthalic Acid - Semaglutide for Type 2 Diabetes – Gentolex Detail:

Product Detail

Name  Semaglutide
CAS number  910463-68-2
Molecular formula  C187H291N45O59
Molecular weight  4113.57754
EINECS Number  203-405-2

Synonyms

Sermaglutide; Semaglutide fandachem; Semaglutide impurity; Sermaglutide USP/EP; semaglutide; Sermaglutide CAS 910463 68 2; Ozempic, 

Description

Semaglutide is a new generation of GLP-1 (glucagon-like peptide-1) analogs, and semaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which has a better effect in the treatment of type 2 diabetes. Novo Nordisk has completed 6 Phase IIIa studies of semaglutide injection, and submitted a new drug registration application for semaglutide weekly injection to the U.S. Food and Drug Administration (FDA) on December 5, 2016. A Marketing Authorization Application (MAA) was also submitted to the European Medicines Agency (EMA).

Compared with liraglutide, semaglutide has a longer aliphatic chain and increased hydrophobicity, but semaglutide is modified with a short chain of PEG, and its hydrophilicity is greatly enhanced. After PEG modification, it can not only bind closely to albumin, cover the enzymatic hydrolysis site of DPP-4, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation.

Application

Semaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which is more effective in treating type 2 diabetes.

Bioactivity

Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC0113-0217) is a long-acting glucagon-like peptide 1 (GLP-1) analog, an agonist of GLP-1receptor, with a potential type 2 Therapeutic efficacy of diabetes mellitus (T2DM).

Quality System

In general, quality system and assurance is in place covering all stage of production of the finished product. Adequate manufacturing and control operations are performed in compliance with the approved procedures/ specifications. Change control and Deviation handling system is in place, and necessary impact assessment and investigation were conducted. Proper procedures are in place to ensure quality of product prior to release into the market.


Product detail pictures:

Renewable Design for 3-Nitrophthalic Acid - Semaglutide for Type 2 Diabetes – Gentolex detail pictures

Renewable Design for 3-Nitrophthalic Acid - Semaglutide for Type 2 Diabetes – Gentolex detail pictures


Related Product Guide:

Our target is always to satisfy our customers by offering golden support, superior value and high quality for Renewable Design for 3-Nitrophthalic Acid - Semaglutide for Type 2 Diabetes – Gentolex , The product will supply to all over the world, such as: Russia, Costa Rica, Mauritius, Welcome to visit our company and factory, there are various products displayed in our showroom that will meet your expectation, meanwhile, if you are convenient to visit our website, our sales staff will try their efforts to provide you the best service
  • The manufacturer gave us a big discount under the premise of ensuring the quality of products, thank you very much, we will select this company again.
    5 Stars By Sandy from Mumbai - 2017.10.27 12:12
    We have been looking for a professional and responsible supplier, and now we find it.
    5 Stars By Karen from Romania - 2018.05.15 10:52
    Write your message here and send it to us